Literature DB >> 19273546

Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants.

Y Izumi1, K Tokuda, Ka O'Dell, Cf Zorumski, T Narahashi.   

Abstract

Oseltamivir (Tamiflu), a neuraminidase inhibitor, is widely used for treatment of influenza. Because abnormal behaviors have been observed in some Japanese teenagers following oseltamivir use, its safety has been questioned. Oseltamivir is known to alter neuronal function and behavior in animals, particularly when administered in combination with ethanol. Based on this, it has been hypothesized that interactions of oseltamivir with other drugs may result in altered CNS excitability in this study. It has been found that injection of ephedrine and caffeine overcame inactivity induced by oseltamivir and ethanol but did not alter changes in novelty seeking behavior in a Y-maze test. In ex-vivo hippocampal slices, oseltamivir carboxylate (OTC), an active form of oseltamivir, alters excitability in the absence of ethanol. In slices pretreated with OTC, long-term depression (LTD), a form of synaptic plasticity that is correlated with Y-maze performance was not altered if caffeine or ephedrine was administered individually. However, LTD could not be induced in slices pretreated with OTC if caffeine and ephedrine were administered simultaneously. These observations suggest that combination of oseltamivir with other neurostimulants may alter synaptic plasticity and this may contribute to behavioral changes associated with the drug.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19273546      PMCID: PMC2654582          DOI: 10.1177/0960327109102367

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  38 in total

1.  Spatial performance correlates with long-term potentiation of the dentate gyrus but not of the CA1 region in rats with fimbria-fornix lesions.

Authors:  K Nakao; Y Ikegaya; M K Yamada; N Nishiyama; N Matsuki
Journal:  Neurosci Lett       Date:  2001-07-20       Impact factor: 3.046

2.  Plasma membrane ganglioside sialidase regulates axonal growth and regeneration in hippocampal neurons in culture.

Authors:  J A Rodriguez; E Piddini; T Hasegawa; T Miyagi; C G Dotti
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

Review 3.  Ephedra in perspective--a current review.

Authors:  Ehab A Abourashed; Abir T El-Alfy; Ikhlas A Khan; Larry Walker
Journal:  Phytother Res       Date:  2003-08       Impact factor: 5.878

Review 4.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Ethanol and pentobarbital in combination increase blood-brain barrier permeability to horseradish peroxidase.

Authors:  P A Stewart; E M Hayakawa; P L Carlen
Journal:  Brain Res       Date:  1988-03-08       Impact factor: 3.252

6.  Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.

Authors:  D J Sweeny; G Lynch; A M Bidgood; W Lew; K Y Wang; K C Cundy
Journal:  Drug Metab Dispos       Date:  2000-07       Impact factor: 3.922

7.  Neuraminidase activity in different regions of the seizing epileptic and non-epileptic brain.

Authors:  Alfonso Boyzo; José Ayala; Rafael Gutiérrez; Jorge Hernández-R
Journal:  Brain Res       Date:  2003-02-28       Impact factor: 3.252

8.  Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Authors:  S S Jhee; M Yen; L Ereshefsky; M Leibowitz; M Schulte; B Kaeser; L Boak; A Patel; G Hoffmann; E P Prinssen; C R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

9.  Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice.

Authors:  Stanley M Crain; Ke Fei Shen
Journal:  Brain Res       Date:  2004-01-09       Impact factor: 3.252

10.  Oseltamivir (Tamiflu) unsafe in infants under 1 year old.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2004-02-03       Impact factor: 8.262

View more
  5 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Neuraminidase inhibition primes short-term depression and suppresses long-term potentiation of synaptic transmission in the rat hippocampus.

Authors:  Alina Savotchenko; Arthur Romanov; Dmytro Isaev; Oleksandr Maximyuk; Vadym Sydorenko; Gregory L Holmes; Elena Isaeva
Journal:  Neural Plast       Date:  2015-01-31       Impact factor: 3.599

3.  Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir.

Authors:  Miki Hiasa; Yumiko Isoda; Yasushi Kishimoto; Kenta Saitoh; Yasuaki Kimura; Motomu Kanai; Masakatsu Shibasaki; Dai Hatakeyama; Yutaka Kirino; Takashi Kuzuhara
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

4.  The mechanisms of delayed onset type adverse reactions to oseltamivir.

Authors:  Rokuro Hama
Journal:  Infect Dis (Lond)       Date:  2016-06-02

Review 5.  The mechanisms of sudden-onset type adverse reactions to oseltamivir.

Authors:  R Hama; C L Bennett
Journal:  Acta Neurol Scand       Date:  2016-06-30       Impact factor: 3.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.